Successful Use of Oxandrolone in the Prophylaxis of Hereditary Angioedema: A Case Report

Amin J. Barakat - Pediatrics/Pediatric nephrology

Successful Use of Oxandrolone in the Prophylaxis of Hereditary Angioedema:
A Case Report

Amin J. Barakat, M.D, Anthony J. Castaldo, M.P.A.

Pediatric Asthma, Allergy and Immunology, 1999, 13 (4) 189-193.

ABSTRACT

Hereditary angioedema (HAE) is a rare autosomal dominant disorder typified by a deficiency or dysfunction of C1-esterase inhibitor (C1-INH), and characterized clinically by swelling of the extremities, severe episodic abdominal pain, and sometimes upper airway obstruction. This paper reports for the first time the successful use of oxandrolone in the prophylaxis of HAE in a 14-year-old girl. Oxandrolone has comparatively milder side effects and less potential for hepatotoxicity and virilization than other attenuated androgens used in the prophylaxis of this disease. We believe oxandrolone should be considered as an alternative androgen therapy for children and adults with HAE, particularly females experiencing untoward side effects from danazol or stanozolol, and patients who are not adequately controlled on maximum doses of androgens currently prescribed for HAE.

INTRODUCTION

Hereditary angioedema (HAE) is a rare autosomal dominant disorder typified by a deficiency or dysfunction of C1-esterase inhibitor (C1-INH), an alpha-2-globulin synthesized in the liver. The disease is characterized by episodic swelling of the extremities, face, bowel wall and upper airway. Long-term prophylaxis for symptoms of the disease has been successfully achieved by the use of the 17 alpha alkylated androgens, danazol and stanozolol. There is currently no approved treatment for children with HAE. Additionally, many women experience untoward side effects from the androgens currently being used for HAE prophylaxis. The purpose of this paper is to report the successful use of oxandrolone (17B-hydroxy-17a-methyl-2-oxa-5a-androstan-3-one) for HAE prophylaxis in a 14-year-old girl with severe HAE symptoms, and to review treatment options in this disease.

CASE REPORT

The patient is a 14-year-old white girl who gives history of episodic erythematous rash and mild swelling of the extremities since the age of 18 months. At age 3 1/2, she started to have attacks of episodic colicky abdominal pain associated with nausea and vomiting. The abdominal pain, which occurred every two weeks and lasted 24-72 hours, was severe and excruciating, and it consistently followed the appearance of generalized erythema mottling by about 48 hours. The pain and gastrointestinal symptoms did not respond to sedatives or antiemetics. There were no respiratory or laryngeal symptoms. Family history showed symptomatic HAE in the patient's father, paternal grandfather, a paternal uncle and her father's paternal grandmother. Physical examination at age 14 revealed a healthy looking female with a height of 66 1/4 in., weight 142 lbs., blood pressure 120/70 and Tanner stage V development. Laboratory studies over the years revealed a C1 esterase inhibitor (C1-INH) serum level of 4.7 to 5.1 mg/dl (normal 7.8-23.4 mg/dl) and a functional C1-INH of 7 to 41% (normal 67%). Complete blood count, liver and renal functions and serum complement C3 and C4 were all normal.

At age five, the patient was treated with danazol (200-400 mg) in a single dose as soon as the rash appeared. Danazol markedly reduced the frequency of abdominal pain and the occurrence of the rash. She tolerated the treatment well, and there was no evidence of virilization or adverse effects during that period.

Over the years, and in order to reduce the frequency and severity of attacks, the dose of danazol was increased gradually and at age 9 it was given daily. At age 13, a dose of 2,000 mg/week was associated with a weight gain of 20 lbs. over a period of one year. Serum testosterone level went up from 21 mg/dl to 91 mg/dl, but she showed no evidence of clinical virilization. Reduction of the danazol dose resulted in the return of weekly episodes of severe abdominal pain. Treatment with Epsilon Amino Caproic Acid (10g/day) had no effect on the frequency and severity of symptoms. Fresh frozen plasma was administered and successfully resolved a particularly severe acute gastrointestinal attack that had lasted 5 days. At this time, the patient was started on oxandrolone (0.1 mg/kg/day).

Oxandrolone had a remarkable effect on reducing the frequency and severity of the attacks and throughout 12 months of therapy, her disease was better controlled than at any time during her life. She experienced comparatively mild attacks less than once every 12 to 16 weeks at an average dose of 7.5 mg/day. The bloated, puffy appearance and the weight gain that accompanied danazol therapy disappeared. Her physical examination continued to be normal.

Testosterone levels dropped to a normal level of 20 mg/dl. ACTH, luteinizing hormone, cortisol, follicular stimulating hormone, progesterone levels, renal and hepatic function studies continued to be normal. C1-INH level persisted to be low at 3.9 mg/dl (normal 7.8-23.4 mg/dl).

DISCUSSION

Originally described by Osler in 1888, hereditary angioedema (HAE) is a rare autosomal dominant disorder occurring in 1/10,000 to 1/50,000 individuals, and caused by a congenital defect of the C1-esterase inhibitor (C1-INH), an alpha-2-globulin that is synthesized in the liver. (1,2) Our patient had low quantitative and functional C1-INH and a strong family history of HAE. Her father was shown to have a defect on his C1-INH gene consisting of a single nucleotide insertion at 4460 (S198) leading to a stop signal 3 codons downstream, and resulting in a truncated non-functional C1 inhibitor protein. The normal C4 complement in this patient is not against the diagnosis of HAE.(2) Two types of the disease are known. Type I is characterized by low C1-INH levels and affects about 85% of patients, while type II affects the other 15% and is characterized by normal or elevated levels of the inhibitor that is functionally inactive. Clinically, the disease presents with episodic swelling of the extremities, face, bowel wall, and upper airways and carries significant morbidity. The attacks may be spontaneous or may be triggered by physical trauma or emotional stress. While extremity swelling is a nuisance that most patients are able to tolerate, submucosal swelling of the gastrointestinal tract gives severe recurrent colicky abdominal pain in 75%-90% of patients.(3) The abdominal pain is usually associated with nausea and vomiting and may mimic an acute surgical abdomen. Involvement of the upper airway results in dysphagia, hoarseness and laryngeal obstruction which may be life threatening.

C1-INH is central to the regulation of the complement, coagulation, and contact (kinin forming) systems. It is a member of the serine protease inhibitor (serpin) family and acts as a suicide protein by forming a stable bond with target proteases.(4) C1-INH inhibits C1r and C1s in the complement system, factor XII and kallikrein in the contact system, and factor XI in the coagulation system. Patients with HAE have low plasma levels of C4 which is the substrate of the C1r-C1s complex.(4) C1-INH deficiency results in an unrestricted activation of these systems and the release of vasoactive peptides that cause episodic attacks of angioedema. The longstanding debate over which peptide is the primary mediator of HAE attacks--C2 kinin or bradykinin, may have been resolved in favor of bradykinin. Nussberger et al reported plasma bradykinin levels up to 12 times higher than normal in patients experiencing a HAE attack.(5)

The treatment of choice for severely affected patients is prophylaxis with attenuated androgens, and danazol, a 17-a-ethinyltestosterone derivative, has been widely used since the mid 1970's.(6,7) The exact mechanism of action of danazol in this disease is not known; however, this medication produces a rise in C1-INH level in HAE patients, and usually results in the disappearance or improvement of their clinical symptoms.(8) Experience with danazol in children has been limited, and was the subject of a previous paper describing the same patient.(9) Danazol prophylaxis was successful and well tolerated by our patient. However, after eight years of treatment, she developed severe weight gain and an elevated testosterone level necessitating discontinuation of the medicine and search for other alternatives. Although no longer widely used, antifibrinolytics are considered safe and in many patients result in a notable decrease in the frequency and severity of the angioedema. This treatment may be considered in patients who are unable to take androgens.(14) FFP has been shown to be effective for prophylaxis before surgical and dental procedures and has also been useful for management of acute attacks.(11) Although concerns over the potential for viral transmission have limited the use of FFP, the recent availability of viral inactivated FFP could result in more widespread use. FFP treatment of acute attacks, however, is controversial because of a theoretical risk that replenishing complement components could exacerbate an attack.(11) C1-INH concentrate in a dose of 25 plasma units/kg intravenously has been shown to be a safe and effective therapy for acute attacks as well as prophylaxis, and has been available in Europe for many years. C1-INH treatment resolves the angioedema in 30 minutes to two hours with complete remission in 24 hours. (11,12) C1-INH has not yet been approved for use in the United States notwithstanding a double blind randomized crossover study that concluded it was safe and effective for both prophylaxis and acute attack therapy.(13) A C1-INH concentrate phase 3 clinical trial is now underway.

Our patient responded to therapy with viral inactivated FFP for an acute abdominal attack, but a trial with Epsilon Amino Caproic Acid failed. At that time, we decided to try oxandrolone which we assumed should be efficacious for HAE prophylaxis since other 17 alpha alkylated androgens had been used successfully for almost two decades.(7) To our knowledge, the use of this medication in HAE has not been previously reported. Oxandrolone is 17(beta)-hydroxy-17(alpha)-methyl-2-oxa- 5(alpha)-androstan-3-one almost identical to methyltestosterone, one of the first steroids shown to be effective in preventing HAE attacks. It has a longstanding record of safe use in treating Turner's Syndrome in girls and constitutionally delayed growth and puberty in boys.(14) At recommended doses of < 0.1 mg per kilogram body weight, oxandrolone has generally not been associated with inappropriate aging of bone, provided that treatment is withheld from boys and girls with a bone age of less than 8 to 9 years.(14)

Because of its weak androgenic properties, it would appear that oxandrolone could be better tolerated than the other widely used prophylactic agents, particularly by women. Data compiled by the drug's US manufacturer indicate very few untoward side effects; out of over 400 patients (both males and females) taking oxandrolone doses ranging from 5 to 10 mg/day, three reported acne and 2 showed signs of hirsutism. In contrast, long-term studies that evaluated danazol and stanozolol have reported a high incidence of side effects in women, including menstrual abnormalities, weight gain myalgias and transaminase elevations.

All of the 17 alpha alkylated androgens carry warnings about hepatotoxicity, peliosis, and liver cell tumors. While the tumors are mostly benign, fatal malignant tumors have been reported. Withdrawal of the drug results in complete disappearance of the peliosis and regression or cessation of progression of benign tumors. It would appear that these complications occur to a lesser extent with oxandrolone than with other drugs in the class which are almost completely metabolized in the liver. In contrast, one third of oxandrolone is excreted unchanged in the urine and the rest undergoes considerably less metabolic transformation in the liver. (15) Patients on long-term androgen therapy should receive the lowest dose possible and should have annual liver ultrasonography. Androgens are contraindicated in patients with pre-existing cardiac, renal, or hepatic disease. In children, careful monitoring is required because androgen therapy may accelerate bone maturation without producing compensatory gain in linear growth. The presence of this adverse effect results in compromised adult height. Women should be observed for signs of virilization (deepening of the voice, hirsutism, acne, and clitoromegaly). Discontinuation of drug therapy at the time of evidence of mild virilism is necessary to prevent irreversible virilization.

We know of another 38-year-old patient with Type 2 HAE who was experiencing regular severe attacks of gastrointestinal and extremity edema despite treatment with 800 mg/day of danazol. This patient was free from major attacks for 3 months on oxandrolone 20mg/day and experienced no untoward side effects.

CONCLUSION

There is currently no approved treatment for children with severe HAE symptoms, although the literature indicates that antifibrinolytics should be the first therapy attempted. Long term prophylaxis for patients with HAE has been successfully achieved by the use of androgens and antifibrinolytics. In this paper, we report the use of oxandrolone for the first time in the prophylaxis of HAE. In our opinion, oxandrolone could have a role in the prophylactic therapy of certain severely affected children and adults with HAE who cannot tolerate, or do not respond to antifibrinolytics and other attenuated androgens. Compared to other attenuated androgens, oxandrolone has comparatively milder side effects and less potential for hepatotoxicity and virilization even at doses as high as 20-40 mg/day.

REFERENCES

Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C1-esterase. Am J Med 1963;35: 37-44.
Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Int Med 1976;84: 580-593.
Schonfeld JV, Olbricht T, Breuer N. Hereditaires angiooderm type 1 mit vorwieggend abdomineller symptomatik. Dtsch Med Wochenschr 1991;116: 973-976.
Ciccardi M, Agostoni A. Hereditary angioedema. N Engl J Med 1996;334: 1666-1667.
Nussberger J, Cugno M, Amstutz C, Ciccardi M, Pellacani A, Agostoni A. Plasma bradykinin in angioedema. Lancet 1998;351: 1693-1697.
Ciccardi M, Bergamaschini L, Cugno M, Hack E, Agostoni G, Agostoni A. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol 1991;87: 768-773.
Ciccardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997;99: 194-196.
Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. N Engl J Med 1976;295: 1444-1448.
Barakat AJ, Castaldo AJ. Hereditary angioedema: danazol therapy in a 5-year old child. Am J Dis Child 1993;147: 931-932.
Van Dellen RG. Long term treatment of C1 inhibitor deficiency with epsilon-aminocaproic acid in two patients. Mayo Clin Proc 1996;71: 1175-1178.
Winewisser J, Rossi M, Spath P, Burgi H. Type 1 hereditary angioedema. Variability of clinical presentation and course within two large kindreds. J Intern Med 1997;241: 39-46.
Orfan NA, Kolski GB. Angioedema and C1 inhibitor deficiency. Ann Allergy 1992; 69: 167-172.
Waytes, AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996;334: 1630-1634.
Blizzard RM, Hindmarsh PC, Stanhope R. Oxandrolone therapy: 25 years experience. Growth: Genetics and Hormones 1991;7: 1-6.
Karim A, Ranney RE, Zagarella J, Maibach HI. Oxandrolone disposition and metabolism in man. J Clin Endocrinol Metab 1962;22: 921-924.